We investigated the effects of anidulafungin alone and in combination with amphotericin B against 2
Brain and kidney fungal burdens were determined at day 4 postinfection by CFU count and qPCR 3 based on that described by Bowman et al. (5) . 4
Histopathology analysis was performed at day 4 postinfection (4). The number of fungal 5 microabscesses was evaluated in 20 consecutive microscopic fields. Each section was classified 6 based on the number of fungal microabscesses as follows: absence (-) , <5 (+), ≥5 to ≤20 (++), >20 7 (+++). 8
The in vitro results were analysed by either Mann-Whitney U test or Student's t-test considering a P 9 value of P<0.05 as significant. Survival and tissue burden studies were analysed by log rank and 10
Mann-Whitney U test, respectively. Due to multiple comparison, a P value of <0.016 was 11 considered as significant. 12 Our in vitro results are shown in table 1. Overall, AFG MECs were significantly lower than AMB 13
MICs and indifference was the only type of interaction among the two drugs. 14 MFCs values were all >16 µg/ml for AFG, while the combination values were statistically lower 15 than those of AFG alone, but not of AMB alone. 16
The metabolic activity studies either on conidia or on hyphae are presented in figure 1 . 17 AFG, AMB and the combination regimens showed a dose-dependent reduction of metabolic 18 activity against conidia, but generally the combination was not more effective than the most active 19 drug alone. Against the hyphae, AMB showed a decreased activity, while AFG was not active. The 20 combination showed to be effective, but not more than AMB alone. 21
The in vivo results are shown in figure 2. In studies #1 and #2, all drug regimens prolonged 22 significantly the survival over that of control animals. In both studies, combination-treated group 23 did not increase significantly the survival time with the respect to AMB-and AFG-treated groups. 24
In study #3, AFG at 5 mg/kg/day and the combination regimen, but not AMB at 0.5 mg/kg/day, 25 Consistent with these data, a decreased number of fungal microabscesses were observed in kidney 6 tissues, but not in brain tissues, of mice treated with AFG at 5 mg/kg/day (figure 3). 7
Our AFG MEC values were similar to those previously reported for A. fumigatus isolates (12,22). In 8 agreement with a previous study conducted by Philip et al. (28) , AFG used in combination with the 9 polyene yielded an indifferent type of interaction. 10
Our in vivo results showed that AFG given at 1 and 5 mg/kg/day were effective at prolonging the 11 survival. These data correspond to those already reported in other experimental models of 12 aspergillosis (26,32). 13
Here, we found that the combination was not more effective than the most active drug alone in all 14 three survival experiments. 15
In terms of kidney tissue burdens, we found that AFG given at 5 mg/kg/day, but not at 1 mg/kg/day, 16 reduced fungal burden with respect to untreated controls. The combination was not more active than 17 AFG alone. Several published studies have already explored the effects of echinocandins other than 18 AFG combined with various AMB formulations against Aspergillus spp.. With the exception of two 19 studies suggesting beneficial effects of combined therapies (i.e.:CAS+AMB, Micafungin+AMB) 20 over the monotherapies (11,30), the remaining experiments showed that combinations did not 21 enhance the effects of the most active single drug (8,9,13,15,18,31).
We showed that neither single drugs nor combinations were active in brain tissues. The lack of 23 AFG efficacy in brains, but not in kidneys, might be explained by its pharmacokinetics features. Each strain was tested in triplicate. In study #1, the animals were infected with 1.5 x 10 7 conidia/mouse and treated with AMB at doses of 1 mg/kg/day, AFG at 1 mg/kg/day and the respective combination regimen; in study #2, the mice were infected with 3.5 x 10 5 conidia/mouse and treated with AMB at 1 mg/kg/day, AFG at 1 mg/kg/day and the respective combination; in study #3, the animals were infected with 3.2 x 10 6 A. fumigatus conidia/mouse and treated with AMB at 0.5 mg/kg/day, AFG at 5 mg/kg/day and the corresponding combination. The therapies were started 2 hrs postinfection (day 0) and continued through day 4 postinfection (5 consecutive days). There were from 9 to 16 mice in each group. Asterisks indicate groups with prolonged survival over controls (due to multiple comparison, P values of < 0.016 were considered statistically significant). 
